CAR T-Cell Therapy Shown Safe, Effective in MCL With CNS Involvement
While CAR T-cell therapies have changed the treatment landscape for patients with hematological malignancies, data on the outcomes of CAR T-cell therapy among patients with MCL and CNS metastases are limited. The study authors noted prior research demonstrating a prognosis of less than 5 months in these rare cases.
The new study aimed to gain insight into the efficacy and safety of CAR T-cell therapy in this patient population through a retrospective, multicenter analysis.
Researchers identified 10 patients with MCL and a history of SCNS involvement who were treated with anti-CD19 CAR T-cell therapy at 3 academic centers in the United States. Patient data were collected from electronic medical records and included patient demographics, disease characteristics, prior lines of therapy, the onset and duration of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), available scans, cerebral spinal fluid (CSF) testing results, disease progression, and survival status.
“The results from our cohort of 10 patients with MCL and SCNS disease demonstrate that anti-CD19 CAR T-cell therapy in this population is feasible and efficacious,” the authors concluded. A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement is feasible, but additional research on neurotoxicity is needed. The findings were published in the British Journal of Haematology.
ارسال به دوستان